Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899594 · ClinicalTrials.gov registry record · Early Phase 1
Psilocybin for Methamphetamine Addiction
A Early Phase 1 study of Methamphetamine Use Disorder, sponsored by Kevin Murnane.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06899594 is a Early Phase 1 study of Methamphetamine Use Disorder that is actively recruiting participants, run by Kevin Murnane. The registered enrollment target is 20 participants, below the 54-participant average among 12 other Methamphetamine Use Disorder trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06899594, a Early Phase 1 study of Methamphetamine Use Disorder, is actively recruiting participants, sponsored by Kevin Murnane.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.
Conditions Studied
Interventions
- DRUG Psilocybin 25 mg
Study Locations (1)
Louisiana
- LSU Health Shreveport - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-04 |
| Est. Completion | 2027-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06899594
The ClinicalTrials.gov registry entry for NCT06899594 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 54-participant average among 12 other Methamphetamine Use Disorder trials with a reported enrollment target (63% lower). The listed sponsor is Kevin Murnane, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Methamphetamine Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin 25 mg is the first listed.
NCT06899594 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT06899594 about?
NCT06899594 is a clinical study titled "Psilocybin for Methamphetamine Addiction". The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on met...
What is the current status of trial NCT06899594?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-04-04. Estimated completion is 2027-03.
What conditions does trial NCT06899594 study?
This clinical trial studies the following conditions: Methamphetamine Use Disorder.
What interventions are being tested in trial NCT06899594?
The interventions under investigation include: Psilocybin 25 mg (DRUG).
Who is sponsoring clinical trial NCT06899594?
This trial is sponsored by Kevin Murnane, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06899594 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Methamphetamine and Troriluzole
RECRUITING · Early Phase 1
-
Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
RECRUITING · Phase 2
-
Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder
RECRUITING · NA
-
Deep TMS of Neural Circuits Associated With Stimulant Use Disorder
RECRUITING · NA
-
Non-Abstinence Outcomes in Methamphetamine Use Disorder
RECRUITING · NA
-
Methamphetamine Cue-reactivity
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.